Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated November 10, 2025, reports a transaction in the company's own shares. The filing details a share repurchase executed on November 7, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing focuses exclusively on capital structure and share repurchase activity. It does not provide revenue, profit, cash flow, margin, or debt figures.
- Shares Purchased (Nov 7, 2025): 170,000 ordinary shares.
- Price Range: Lowest 1,757.50p; Highest 1,788.50p.
- Volume-Weighted Average Price (VWAP): 1,772.64p.
- Cumulative Buyback (since Sept 30, 2025): 8,159,000 ordinary shares.
- Treasury Shares Held: 255,623,844 ordinary shares.
- Shares in Issue (excluding Treasury): 4,059,804,530 ordinary shares.
- Total Voting Rights: 4,059,804,530.
- Treasury Voting Rights Percentage: 6.30%.
Material Changes
There are no material changes to financial performance metrics reported in this filing. The primary change is the reduction of shares in issue and the increase in treasury shares following the November 7 repurchase. The filing confirms the updated denominator for shareholder notification calculations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding future operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the "Risk Factors" section of the 2024 Annual Report on Form 20-F and the Q3 Results for 2025. No unusual items or contingencies are disclosed.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the updated share count (4,059,804,530) for calculating ownership thresholds under DTR 5.5.1R.
- Review the 2024 Form 20-F and Q3 2025 results for the specific risk factors referenced in the cautionary statement.
- Monitor future 6-K filings for subsequent repurchase activity under the non-discretionary agreement.